Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2023-08-24 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
关于2023年半年度报告披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (308 characters) from a company about the disclosure of its 2023 semi-annual report. It states that the semi-annual report and its summary have been published on an official disclosure website and advises investors to review it. There is no actual financial data or detailed report content included in this document. According to the 'MENU VS MEAL' rule, such a brief notice that a report has been published and is available elsewhere is classified as a Report Publication Announcement (RPA), not the report itself (IR).
2023-08-24 Chinese
第四届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 24th meeting of the 4th Board of Directors of the company. It includes details about the meeting date, attendance, and voting results on specific agenda items such as approval of the 2023 semi-annual report and a special report on the use of raised funds. The document does not contain the actual semi-annual report or detailed financial data but refers to the report being disclosed elsewhere (on the cninfo website). This fits the definition of a Board/Management Information filing, as it announces board meeting decisions and approvals rather than providing the full report itself.
2023-08-24 Chinese
独立董事关于第四届董事会第二十四次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors regarding the company's 2023 semi-annual report on the use and storage of raised funds, as well as related matters such as related party fund occupation and guarantees. It references a specific report (the 2023 semi-annual fundraising usage report) and provides an independent opinion on its accuracy and compliance. The document is relatively short (763 characters) and does not contain detailed financial statements or substantive financial data itself, but rather an opinion on a report. This fits the profile of a Regulatory Filing (RNS) as it is a compliance-related statement and independent director opinion rather than the report itself or a full interim report.
2023-08-24 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and shareholder information for the half-year period. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report for comprehensive information. The presence of substantive financial data and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document length is 2607 characters, which is sufficient for a summary but still contains actual financial figures, so it is not merely an announcement or a report publication notice. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2023
2023-08-24 Chinese
上市公司2023年1-6月非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the first half of 2023. It includes financial figures but is primarily a tabular summary of related party transactions rather than a comprehensive financial report. The document length is short (1423 characters), and it does not contain full financial statements or detailed analysis typical of interim or annual reports. It also does not fit into categories like audit reports, earnings releases, or management reports. The content is more aligned with disclosures related to related party transactions, which are often part of regulatory filings or compliance disclosures. Given the short length and nature of the content, it is best classified as a Regulatory Filing (RNS), which serves as a fallback for miscellaneous filings that do not fit other categories.
2023-08-24 Chinese
中天国富证券有限公司关于拓新药业集团股份有限公司2023年半年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a '2023 Half-Year Continuous Supervision Tracking Report' by a sponsoring securities company regarding a listed company. It details the sponsor's review and supervision activities over the half-year period, including information disclosure, internal controls, fundraising supervision, governance, and other compliance matters. It also mentions changes in the sponsor representatives and confirms no regulatory sanctions during the period. The document is a monitoring and supervisory report related to the half-year period but does not contain full financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report (IR). Instead, it is a specialized supervisory report by the sponsor on compliance and governance matters during the half-year. This type of document aligns best with the category of Regulatory Filings (RNS), as it is a regulatory compliance and supervision report rather than a full financial report or announcement. The document length is short (2029 characters), and it contains substantive content rather than just an announcement or certification, so it is not RPA or purely certification. Therefore, the best classification is Regulatory Filings (RNS).
2023-08-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.